Literature DB >> 101252

Serum inhibitors of desialylated glycoprotein binding to hepatocyte membranes.

J S Marshall, S Williams.   

Abstract

Identification of the material present in human serum which is responsible for inhibition of binding of desialylated glycoproteins to rat hepatocyte membranes was accomplished by means of affinity chromatography using Sephadex to which the galactose-specific lectin, Ricinus Communis Agglutinin (RCAI) was covalently bound. RCAI-Sephadex was capable of extraction of virtually all of the inhibitory activity from cirrhotic serum. The RCA I-bound inhibitory activity could be eluted with 0.05 M D-galactose. The D-galactose eluate when subjected to radioimmunoelectrophoresis against a number of specific antibodies to human serum glycoproteins produced arcs corresponding to alpha 1-acid glycoprotein, alpha2-macroglobulin, IgG, IgA, and IgM. In another experiment putative terminal galactosyl groups of desialylated glycoproteins in the D-galactose eluate from cirrhotic serum exposed to RCAI-Sephadex were labelled with tritiated borohydride after treatment with galactose oxidase. Subsequent gel electrophoresis showed peaks of radioactivity throughout the area of the gel corresponding to protein molecular weights of the 19 S, 7 S, and 4 S classes. It thus appears that a heterogeneous population of desialylated serum glycoproteins accounts for the inhibition of binding of desialylated glycoprotein to the hepatocyte membrane and that these desialylated glycoproteins are present in small amounts in normal human serum and in greatly increased quantities in serum from patients with cirrhosis.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 101252     DOI: 10.1016/0304-4165(78)90452-x

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  8 in total

1.  The influence of N-acetylneuraminic acid on the properties of human orosomucoid.

Authors:  M L Friedman; J R Wermeling; H B Halsall
Journal:  Biochem J       Date:  1986-05-15       Impact factor: 3.857

Review 2.  Clinical pharmacokinetics of alfentanil, fentanyl and sufentanil. An update.

Authors:  J Scholz; M Steinfath; M Schulz
Journal:  Clin Pharmacokinet       Date:  1996-10       Impact factor: 6.447

Review 3.  The role of the liver in clearance of glycoproteins from the general circulation, with special reference to intestinal alkaline phosphatase.

Authors:  D K Meijer; H B Scholtens; M J Hardonk
Journal:  Pharm Weekbl Sci       Date:  1982-06-25

4.  Metabolic implications in the elevation of serum activity of intestinal alkaline phosphatase in chronic renal failure.

Authors:  J Stĕpán; T Havránek; E Jelínková; M Straková; J Skrha; V Pacovský
Journal:  Experientia       Date:  1984-08-15

5.  Metabolic implications in the elevation of serum activity of intestinal alkaline phosphatase in chronic renal failure.

Authors:  J Stĕpán; T Havránek; E Jelínková; M Straková; J Skrha; V Pacovský
Journal:  Experientia       Date:  1984-05-15

Review 6.  Alfentanil infusions in patients requiring intensive care.

Authors:  A Bodenham; G R Park
Journal:  Clin Pharmacokinet       Date:  1988-10       Impact factor: 6.447

7.  Scintigraphic evaluation of functional hepatic mass in patients with advanced breast cancer.

Authors:  I Virgolini; G Kornek; J Höbart; S R Li; M Raolerer; H Bergmann; W Scheithauer; T Pantev; P Angelberger; H Sinzinger
Journal:  Br J Cancer       Date:  1993-09       Impact factor: 7.640

8.  Evaluation of GalNAc-siRNA Conjugate Activity in Pre-clinical Animal Models with Reduced Asialoglycoprotein Receptor Expression.

Authors:  Jennifer L S Willoughby; Amy Chan; Alfica Sehgal; James S Butler; Jayaprakash K Nair; Tim Racie; Svetlana Shulga-Morskaya; Tuyen Nguyen; Kun Qian; Kristina Yucius; Klaus Charisse; Theo J C van Berkel; Muthiah Manoharan; Kallanthottathil G Rajeev; Martin A Maier; Vasant Jadhav; Tracy S Zimmermann
Journal:  Mol Ther       Date:  2017-09-07       Impact factor: 11.454

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.